Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but ...

An international study led by a scientist at the University of Ottawa Faculty of Medicine is opening new frontiers in the ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

What if a new combination of cancer drugs could sound an alarm, alerting the body's immune system to invoke a targeted ...

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology. Published in the renowned journal ...

A research team at Kanazawa University, led by Professor Atsushi Mizokami, Associate Professor Koji Izumi and Specially ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.

RASolute 302 findings herald a new standard of care in previously treated patients ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...